Frequency of tobacco smoking among smokers. by Prasanna Herath (20714794)

Subjects:

Correlation of lung function parameters with smoking variables. by Prasanna Herath (20714794)

Subjects:

Anthropometric characteristics of smokers and non-smokers. by Prasanna Herath (20714794)

Subjects:

Respiratory clinical characteristics of smokers and non-smokers. by Prasanna Herath (20714794)

Subjects:

Effect of the smoking factor on lung function parameters (FVC, FEV1, PEF, FEF 25_75). by Prasanna Herath (20714794)

Subjects:

Lung function parameters between smokers and non-smokers. by Prasanna Herath (20714794)

Subjects:

Supplementary file 1_Global variation in antibiotic prescribing guidelines and the implications for decreasing AMR in the future.docx by Emmama Jamil (22005635)

GLM models for predictors of monthly HIV costs. by Drew B. Cameron (10687420)

Subjects:

Median cost (USD) per visit breakdown. by Drew B. Cameron (10687420)

Subjects:

Descriptive statistics (means) for full sample and by lockdown status. by Drew B. Cameron (10687420)

Subjects:

Study sites and number of participants enrolled in the KAP and OOP surveys. by Drew B. Cameron (10687420)

Subjects:

Average cost per visit for HIV and HTN care (absolute vs. relative contributions). by Drew B. Cameron (10687420)

Subjects:

GLM models for predictors of monthly HTN care costs. by Drew B. Cameron (10687420)

Subjects:

Median monthly care costs, projected visits, and hospitalization costs. by Drew B. Cameron (10687420)

Subjects:

Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

Subjects:

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Quality of life scores at baseline (week 0) and the end of chemotherapy (week 18) in participants that met (≥ 150 minutes/week) or did not meet (< 150 minutes/week) WHO’s aerobic e... by Claire M. Douglas (21238238)

Subjects:

Flow of participants through the DHA WIN RCT. Abbreviations: Docosahexaenoic acid (DHA), Docosahexaenoic acid for Women with Breast Cancer in the Neoadjuvant Setting (DHA WIN), ran... by Claire M. Douglas (21238238)

Subjects: